Table 2.
Efficacy of second line H. pylori eradication therapy.
| Regimen | Number | Treatment | Perecent | 95% CI |
| treated | successful | success | ||
| 7 days | ||||
| PPI | 27 | 19 | 70% | 52.8–87.2*$ |
| nitroimidazole | ||||
| tetracycline 500 mg qid | ||||
| DCB 240 mg bid | ||||
| 7 days | ||||
| PPI | 7 | 2 | 28% | 0–61 |
| amoxicillin 1 g bid | ||||
| nitroimidazole | ||||
| 7 days | ||||
| PPI | 1 | 0 | 0% | - |
| clarithromycin 500 mg bid | ||||
| nitroimidazole | ||||
| 7 days | ||||
| PPI | 8 | 4 | 50% | 15.4–84.6 |
| amoxicillin 1 g bid | ||||
| clarithromycin 500 mg bid | ||||
| 7 days | ||||
| RBC 400 mg bid | 18 | 13 | 73% | 52.4–93.6*$ |
| amoxicillin 1 g bid | ||||
| clarithromycin 500 mg bid | ||||
| 7 days | ||||
| RBC 400 mg bid | 5 | 4 | 80% | 45–100 |
| tetracycline 1 g bid | ||||
| nitroimidazole |
* PPI-DCB-N-T and RBC-A-C were significantly more effective than PPI-A-M as second line therapy (both P < 0.05). $ Bismuth-based (PPI-DCB-N-T or RBC-A-C) was more effective that PPI-triple therapy (P < 0.05).